Tharimmune, Inc. (THAR)
(Delayed Data from NSDQ)
$3.00 USD
+0.10 (3.45%)
Updated Aug 15, 2024 03:59 PM ET
After-Market: $3.00 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
THAR 3.00 +0.10(3.45%)
Will THAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for THAR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THAR
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
THAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for THAR
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
Tharimmune appoints David Jones to Scientific Advisory Board
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune appoints David Clarke as strategic advisor
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor